Abbott Laboratories ($ABT) reported solid sales gains in its core laboratory and point-of-care diagnostics lines during the 2014 second quarter, thanks to larger testing volumes and new products. But molecular diagnostics sales declined a bit, affected, in part, by the timing of tenders in the infectious disease business in several emerging markets. Overall, the division produced $1.19 billion in sales during the quarter, 4.8% higher than the same period a year ago. Abbott plans to sell its developed markets generic pharma unit, which will leave its struggling medical device and still-promising diagnostics divisions delivering the bulk of the revenue. Story | Release